Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiogenedWAR:BGD 78 5-Year Yield-on-Cost % is 7.80 as of Aug. 31, 2026, which is 30% above its 10-year median of 6.02. GuruFocus rates WAR:BGD with a GF Score™ of 78/100 and a GF Value™ of zł24.27 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 509 Drug Manufacturers companies, Biogened ranks better than 83.89% on this metric.
Biogened's yield on cost for the quarter that ended in Mar. 2026 was 7.80.
The historical rank and industry rank for Biogened's 5-Year Yield-on-Cost % or its related term are showing as below:
WAR:BGD'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 3.86 Med: 6.02 Max: 8.55
Current: 7.8
During the past 13 years, Biogened's highest Yield on Cost was 8.55. The lowest was 3.86. And the median was 6.02.
WAR:BGD's 5-Year Yield-on-Cost % is ranked better than 83.89% of 509
companies
in the Drug Manufacturers industry
Industry Median: 2.39
vs WAR:BGD: 7.80
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Biogened 5-Year Yield-on-Cost % Related Terms
WAR:BGD vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biogened's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogened 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biogened's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Biogened's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Biogened is calculated as
Biogened (WAR:BGD) has a 5-Year Yield-on-Cost % of 7.80 as of Aug. 31, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Biogened and its competitors. This is 30% above median its historical median of 6.02. Over the past decade, Biogened's 5-Year Yield-on-Cost % has ranged from 3.86 to 8.55. According to the industry distribution chart, Biogened ranks #82 out of 509 companies in the Drug Manufacturers industry, placing it in the top 16.1%.
Is Biogened's 5-Year Yield-on-Cost % too high?
Biogened's current 5-Year Yield-on-Cost % of 7.80 is 30% above median its 10-year median of 6.02. Over the past 10 years, this metric has ranged from a low of 3.86 to a high of 8.55. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.39. Biogened's value of 7.80 is 226.4% above this industry median. Based on the distribution chart, Biogened ranks #82 out of 509 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Biogened has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biogened's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biogened ranks #82 out of 509 companies for 5-Year Yield-on-Cost %. This places Biogened in the top 16% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.39. Biogened's value of 7.80 is 226.4% above this benchmark. Historically, Biogened's own 5-Year Yield-on-Cost % has ranged from 3.86 to 8.55 over the past decade. While the company's 10-year median is 6.02 vs. the industry median of 2.39, Biogened has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.39, based on 509 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biogened's current 5-Year Yield-on-Cost % of 7.80 is 226.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Biogened and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biogened's current 5-Year Yield-on-Cost % is 7.80, which is 30% above median its own 10-year median of 6.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogened stock overvalued right now?
Based on GuruFocus' analysis, Biogened (WAR:BGD) is currently considered Modestly Undervalued. The stock's GF Value™ is zł24.27, compared to a current price of zł19.00 — trading 21.7% below its estimated fair value. The current 5-Year Yield-on-Cost % is 7.80, which is 30% above median its 10-year median of 6.02 and 226.4% above the Drug Manufacturers industry median of 2.39. Biogened's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Biogened (WAR:BGD), the current 5-Year Yield-on-Cost % is 7.80 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biogened (WAR:BGD) Overvalued in 2026?
Based on GuruFocus' analysis, Biogened stock appears to be undervalued.
The current stock price of zł19.00 is trading 21.7% below its estimated GF Value™ of zł24.27.
GuruFocus considers Biogened to be Modestly Undervalued.
Key valuation signals for WAR:BGD:
5-Year Yield-on-Cost %: 7.80 (30% above median its 10-year median of 6.02)
GF Value™: zł24.27 vs. price of zł19.00 (21.7% below fair value)
Industry Position: 226.4% above the Drug Manufacturers median (#82 of 509)
No single metric tells the full story. See the WAR:BGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biogened SA is involved in manufacturing cosmetic and hygiene products. It also designs, produces, and markets safe, effective dermo-cosmetics under the Dermedic brand. The company's products include Dermocosmetics, Thermal water, and Pharmaceutical manufacturing conditions.
78GF Score
Get the complete analysis for WAR:BGD
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:BGD has been successfully added to your 
